Genetic Variability in AstraZeneca PLC’s Clopidogrel Response Not Always Overcome by Dosing, University of Maryland Study

ORLANDO, March 29 -- Patients with a genetic variant associated with responsiveness to clopidogrel (Plavix) have double the risk of cardiovascular events even with extreme doses of the drug, according to two studies.

MORE ON THIS TOPIC